26 April 2024
NEWS RELEASE
BHR Biosynex opens new facility to support growth in point of care diagnostics landscape.
BHR Biosynex has celebrated the opening of its new facilities in Nuneaton with a week of events. Marking a significant milestone in the company's history and the broader landscape of point of care testing in the UK, the company welcomed over sixty guests from NHS Trusts, private healthcare providers, and the in vitro diagnostics industry, as well as Rt Hon Marcus Jones MP, and underscores the company's pivotal role in advancing point of care diagnostics over the past 34 years. It not only celebrated BHR Biosynex's historical contributions, such as the introduction of the UK's first handheld cholesterol test, but also set the stage for the future of healthcare diagnostics.
Ramesh Patel, managing director of BHR Biosynex said: “The opening week has given us the perfect opportunity to showcase our premises and our people, but most importantly the ethos of the company. We aim to provide our customers with the innovative point of care solutions they need to deliver quality healthcare services to their patients. I am immensely proud of the team and genuinely excited for the future of BHR Biosynex.”
The significance of point of care diagnostics, as discussed with visitors over the course of the week, cannot be overstated, especially in the context of the UK's healthcare objectives. The dialogue with Rt Hon Marcus Jones MP highlighted how BHR Biosynex's technology aligns with the national healthcare strategy, particularly in enhancing patient pathways, reducing health inequalities, and enabling earlier diagnoses through rapid and convenient testing solutions. As the NHS moves towards more integrated community-based healthcare models, BHR Biosynex's portfolio, including its market-leading CardioChek solution for cholesterol testing, is well positioned to meet these evolving needs.
Originally founded as BHR Pharmaceuticals Ltd in 1990, its acquisition by Biosynex in 2022 is a testament to the company's growth and its strategic role within the global diagnostics market. Looking ahead, BHR Biosynex is poised to further impact the UK healthcare landscape with its new facility, dedicated team, and expanding array of innovative diagnostic solutions. This move not only strengthens its market presence in the UK but also signifies a continued commitment to supporting healthcare professionals and patients alike in achieving better health outcomes. As BHR Biosynex charts its course for the future, it remains at the forefront of the shift towards more accessible and efficient diagnostic practices, embodying the potential of point of care testing to transform healthcare delivery.
Ends
